| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 Oxford University Press
NEWS |
New Drugs Target Hypoxia Response in Tumors
| The first 150 words of the full text of this article appear below. |
We breathe air that is 21% oxygen, but some of our tissues get by on 7%, and many tumor cells on 1% or less. Tumors cope with very low oxygen concentration, or hypoxia, in several ways. The best-studied mechanism is activation of a transcription factor, hypoxia-inducible factor 1 (HIF-1), which has emerged as a promising target for cancer therapy. The first clinical trials of HIF inhibitors are poised to begin, but unanswered questions of HIF biology continue to loom large.
Tumor hypoxia was first described a half-century ago, when R.H. Thomlinson and Louis Gray, Ph.D., of the Mount Vernon Hospital in England, showed that solid tumors contain zones of very low oxygen and that this hypoxia compromised radiation therapy. Abnormal or poor blood vessel growth, a fundamental hallmark of tumors (and one that angiogenesis-inhibiting drugs seek to exploit), was later shown to be the cause. Over the last few decades,
Tumor Promoter or Suppressor?
Finding Drugs
Lingering Doubts
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E.-J. Yeo, J.-H. Ryu, Y.-S. Chun, Y.-S. Cho, I.-J. Jang, H. Cho, J. Kim, M.-S. Kim, and J.-W. Park YC-1 Induces S Cell Cycle Arrest and Apoptosis by Activating Checkpoint Kinases. Cancer Res., June 15, 2006; 66(12): 6345 - 6352. [Abstract] [Full Text] [PDF]
|
|